Cargando…
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613474/ https://www.ncbi.nlm.nih.gov/pubmed/36151141 http://dx.doi.org/10.1038/s41375-022-01707-w |
| _version_ | 1784819999392661504 |
|---|---|
| author | Fiskus, Warren Daver, Naval Boettcher, Steffen Mill, Christopher P. Sasaki, Koji Birdwell, Christine E. Davis, John A. Das, Kaberi Takahashi, Koichi Kadia, Tapan M. DiNardo, Courtney D. Burrows, Francis Loghavi, Sanam Khoury, Joseph D. Ebert, Benjamin L. Bhalla, Kapil N. |
| author_facet | Fiskus, Warren Daver, Naval Boettcher, Steffen Mill, Christopher P. Sasaki, Koji Birdwell, Christine E. Davis, John A. Das, Kaberi Takahashi, Koichi Kadia, Tapan M. DiNardo, Courtney D. Burrows, Francis Loghavi, Sanam Khoury, Joseph D. Ebert, Benjamin L. Bhalla, Kapil N. |
| author_sort | Fiskus, Warren |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9613474 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96134742022-10-29 Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 Fiskus, Warren Daver, Naval Boettcher, Steffen Mill, Christopher P. Sasaki, Koji Birdwell, Christine E. Davis, John A. Das, Kaberi Takahashi, Koichi Kadia, Tapan M. DiNardo, Courtney D. Burrows, Francis Loghavi, Sanam Khoury, Joseph D. Ebert, Benjamin L. Bhalla, Kapil N. Leukemia Letter Nature Publishing Group UK 2022-09-23 2022 /pmc/articles/PMC9613474/ /pubmed/36151141 http://dx.doi.org/10.1038/s41375-022-01707-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Fiskus, Warren Daver, Naval Boettcher, Steffen Mill, Christopher P. Sasaki, Koji Birdwell, Christine E. Davis, John A. Das, Kaberi Takahashi, Koichi Kadia, Tapan M. DiNardo, Courtney D. Burrows, Francis Loghavi, Sanam Khoury, Joseph D. Ebert, Benjamin L. Bhalla, Kapil N. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 |
| title | Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 |
| title_full | Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 |
| title_fullStr | Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 |
| title_full_unstemmed | Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 |
| title_short | Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 |
| title_sort | activity of menin inhibitor ziftomenib (ko-539) as monotherapy or in combinations against aml cells with mll1 rearrangement or mutant npm1 |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613474/ https://www.ncbi.nlm.nih.gov/pubmed/36151141 http://dx.doi.org/10.1038/s41375-022-01707-w |
| work_keys_str_mv | AT fiskuswarren activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT davernaval activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT boettchersteffen activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT millchristopherp activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT sasakikoji activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT birdwellchristinee activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT davisjohna activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT daskaberi activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT takahashikoichi activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT kadiatapanm activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT dinardocourtneyd activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT burrowsfrancis activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT loghavisanam activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT khouryjosephd activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT ebertbenjaminl activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 AT bhallakapiln activityofmenininhibitorziftomenibko539asmonotherapyorincombinationsagainstamlcellswithmll1rearrangementormutantnpm1 |